Stay updated on Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.

Latest updates to the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedFooter revision updated from v3.4.2 to v3.4.3. No study content or user-facing functionality were changed.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedAdded site Revision: v3.4.2. Removed the government funding/operating status notice from the page.SummaryDifference0.5%

- Check44 days agoChange DetectedAdded a government funding notice and a site revision notice (Revision: v3.4.1); removed the previous revision (v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check51 days agoChange DetectedShow glossary toggle added and minor UI label changes (e.g., capitalization in 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data'). The footer revision now shows v3.4.0.SummaryDifference0.2%

- Check65 days agoChange DetectedRevision: v3.3.4 is shown, replacing v3.3.3. No user-facing content or study details appear to be affected.SummaryDifference0.1%

- Check86 days agoChange DetectedAdded a Locations section with Oregon as a study site, updating core participation details. Removed the old Oregon Locations label and the HHS Vulnerability Disclosure link; revision updated to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib Pembrolizumab Combo in Head & Neck Cancer Clinical Trial page.